{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:37:55Z","timestamp":1770460675463,"version":"3.49.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institutes of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS098023"],"award-info":[{"award-number":["R01NS098023"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institutes of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS124882"],"award-info":[{"award-number":["R01NS124882"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood-based biomarkers are crucial for individualized management of multiple sclerosis (MS). Blood neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have shown promising clinical utility in MS, but they are insufficient to guide clinical management. Plasma tau proteins remain underexplored despite the growing evidence of shared pathology in Alzheimer\u2019s disease and MS. We aimed to: (i) assess the utility of plasma tau biomarkers [phosphorylated tau 181 (p-tau181), p-tau217 and total tau (t-tau)] in MS diagnosis, subtyping and prognosis; and (ii) compare their performance with NfL and GFAP. From a clinic-based prospective cohort, we evaluated 160 people with MS [pwMS; 117 with relapsing\u2013remitting MS, 43 with progressive MS (PMS)] and 20 non-MS controls, all with baseline plasma samples. We measured baseline plasma concentrations of p-tau181, p-tau217, t-tau, NfL and GFAP using ultrasensitive immunoassays. We collected demographics, clinical information, and longitudinal multi-modal outcomes (Patient Determined Disease Steps, normalized age-related MS severity score, walking speed, manual dexterity, cognitive performance, retinal nerve fibre layer thickness, total brain volume and grey matter volume) over a median follow-up of 3.0 years (interquartile range, 3.5). Adjusting for demographic and clinical covariates, we evaluated associations between biomarkers and MS diagnosis, subtypes, and prognosis. We examined the enhanced value of tau markers, in addition to NfL and GFAP, for subtype distinction and outcome prediction. Participants were enrolled between 2017 and 2023. Assays were performed in August 2023. Analyses were conducted in December 2024. Participants (n = 180) had a median age of 51 years and were predominantly women (68%) and non-Hispanic white (91%). Compared with controls, pwMS had higher levels of p-tau217 (1.0 versus 0.7\u2005pg\/ml; P = 0.04) and NfL (14.1 versus 9.0\u2005pg\/ml; P &amp;lt; 0.01). Among pwMS, higher p-tau181 (adjusted odds ratio (aOR) [95% confidence interval (CI)] = 2.3 [1.4, 4.1]) and p-tau217 (aOR [95% CI] = 3.0 [1.8, 5.7]) were associated with PMS. These markers improved MS subtype classification accuracy beyond clinical features, NfL and GFAP. Higher baseline p-tau181 and p-tau217 predicted worse disability, functional outcomes and imaging outcomes independent of other biomarkers. Plasma p-tau181 and p-tau217 are promising biomarkers for MS subtype classification and disability prediction, providing complementary information to NfL and GFAP. Further studies to validate their potential clinical utility in guiding MS management are warranted.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf510","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:36:13Z","timestamp":1767098173000},"source":"Crossref","is-referenced-by-count":0,"title":["Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0282-4532","authenticated-orcid":false,"given":"Chen","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Sehrawat","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth L S","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Watterson","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K","family":"Karikari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1500-2589","authenticated-orcid":false,"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA 15260 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"2026020612023815400_fcaf510-B1","first-page":"1","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026020612023815400_fcaf510-B2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2026020612023815400_fcaf510-B3","doi-asserted-by":"crossref","first-page":"e200025","DOI":"10.1212\/NXI.0000000000200025","article-title":"Toward precision phenotyping of multiple sclerosis","volume":"9","author":"Pitt","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"2026020612023815400_fcaf510-B4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"issue":"8","key":"2026020612023815400_fcaf510-B5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: A review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"2026020612023815400_fcaf510-B6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10","key":"2026020612023815400_fcaf510-B7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","article-title":"Body fluid biomarkers for multiple sclerosis\u2014The long road to clinical application","volume":"11","author":"Teunissen","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2026020612023815400_fcaf510-B8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"28","key":"2026020612023815400_fcaf510-B9","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1073\/pnas.1522730113","article-title":"Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins","volume":"113","author":"Br\u00e4ndle","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026020612023815400_fcaf510-B10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.autrev.2015.07.014","article-title":"Peripheral blood biomarkers in multiple sclerosis","volume":"14","author":"D\u2019Ambrosio","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"2026020612023815400_fcaf510-B11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awy006","article-title":"The value of oligoclonal bands in the multiple sclerosis diagnostic criteria","volume":"141","author":"Arrambide","year":"2018","journal-title":"Brain"},{"issue":"11","key":"2026020612023815400_fcaf510-B12","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms23115877","article-title":"Current and future biomarkers in multiple sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2026020612023815400_fcaf510-B13","doi-asserted-by":"crossref","first-page":"e16061","DOI":"10.15252\/emmm.202216061","article-title":"Quantitative protein biomarker panels: A path to improved clinical practice through proteomics","volume":"15","author":"Hartl","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2026020612023815400_fcaf510-B14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000515806","article-title":"Neurofilament light chain levels are associated with disease activity determined by no evident disease activity in multiple sclerosis patients","volume":"84","author":"Szilasiov\u00e1","year":"2021","journal-title":"Eur Neurol"},{"issue":"23","key":"2026020612023815400_fcaf510-B15","doi-asserted-by":"crossref","first-page":"e2457","DOI":"10.1212\/WNL.0000000000009571","article-title":"Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis","volume":"94","author":"Manouchehrinia","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"2026020612023815400_fcaf510-B16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ane.13152","article-title":"Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients","volume":"141","author":"Ferraro","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"2026020612023815400_fcaf510-B17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1177\/13524585221094224","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis","volume":"28","author":"Pauwels","year":"2022","journal-title":"Mult Scler"},{"issue":"1","key":"2026020612023815400_fcaf510-B18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40001-023-01631-4","article-title":"Prediction of clinical progression in nervous system diseases: Plasma glial fibrillary acidic protein (GFAP)","volume":"29","author":"Zheng","year":"2024","journal-title":"Eur J Med Res"},{"key":"2026020612023815400_fcaf510-B19","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"eBioMedicine"},{"issue":"4","key":"2026020612023815400_fcaf510-B20","doi-asserted-by":"crossref","first-page":"fcae209","DOI":"10.1093\/braincomms\/fcae209","article-title":"Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing","volume":"6","author":"Tan","year":"2024","journal-title":"Brain Commun"},{"issue":"10","key":"2026020612023815400_fcaf510-B21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.21037\/atm.2018.04.23","article-title":"Tau in neurodegenerative disease","volume":"6","author":"Gao","year":"2018","journal-title":"Ann Transl Med"},{"issue":"4","key":"2026020612023815400_fcaf510-B22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/17520363.2.4.363","article-title":"Tau as a biomarker of neurodegenerative diseases","volume":"2","author":"Schraen-Maschke","year":"2008","journal-title":"Biomark Med"},{"issue":"1","key":"2026020612023815400_fcaf510-B23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: The story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"2026020612023815400_fcaf510-B24","doi-asserted-by":"crossref","first-page":"e168553","DOI":"10.1172\/JCI168553","article-title":"Tau pathology in neurodegenerative disease: Disease mechanisms and therapeutic avenues","volume":"133","author":"Samudra","year":"2023","journal-title":"J Clin Invest"},{"issue":"7","key":"2026020612023815400_fcaf510-B25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: Analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2026020612023815400_fcaf510-B26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0404.2007.00782.x","article-title":"Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis","volume":"115","author":"Terzi","year":"2007","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"2026020612023815400_fcaf510-B27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1191\/1352458505ms1159oa","article-title":"Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis","volume":"11","author":"Brettschneider","year":"2005","journal-title":"Mult Scler J"},{"issue":"3","key":"2026020612023815400_fcaf510-B28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00702-005-0327-z","article-title":"The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis","volume":"113","author":"Bartosik-Psujek","year":"2006","journal-title":"J Neural Transm"},{"issue":"5","key":"2026020612023815400_fcaf510-B29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00401-010-0671-4","article-title":"Abnormal tau phosphorylation in primary progressive multiple sclerosis","volume":"119","author":"Anderson","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"7","key":"2026020612023815400_fcaf510-B30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awn119","article-title":"Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"131","author":"Anderson","year":"2008","journal-title":"Brain"},{"issue":"5","key":"2026020612023815400_fcaf510-B31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00401-009-0515-2","article-title":"Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis","volume":"117","author":"Anderson","year":"2009","journal-title":"Acta Neuropathol"},{"key":"2026020612023815400_fcaf510-B32","doi-asserted-by":"crossref","first-page":"105801","DOI":"10.1016\/j.msard.2024.105801","article-title":"Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis","volume":"90","author":"Emer\u0161i\u010d","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"685276","key":"2026020612023815400_fcaf510-B33","article-title":"Applying deep learning to accelerated clinical brain magnetic resonance imaging for multiple sclerosis","volume":"12","author":"Mani","year":"2021","journal-title":"Front Neurol"},{"issue":"103994","key":"2026020612023815400_fcaf510-B34","article-title":"The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis","volume":"65","author":"Boorgu","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"2026020612023815400_fcaf510-B35","doi-asserted-by":"crossref","first-page":"e38495","DOI":"10.2196\/38495","article-title":"Predicting multiple sclerosis outcomes during the COVID-19 stay-at-home period: observational study using passively sensed behaviors and digital phenotyping","volume":"9","author":"Chikersal","year":"2022","journal-title":"JMIR Ment Health"},{"issue":"1","key":"2026020612023815400_fcaf510-B36","doi-asserted-by":"crossref","first-page":"fcad300","DOI":"10.1093\/braincomms\/fcad300","article-title":"Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis","volume":"6","author":"Zhu","year":"2024","journal-title":"Brain Commun"},{"issue":"105520","key":"2026020612023815400_fcaf510-B37","article-title":"Hippocampal subfields and thalamic nuclei associations with clinical outcomes in multiple sclerosis: An ultrahigh field MRI study","volume":"86","author":"Santini","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"105762","key":"2026020612023815400_fcaf510-B38","article-title":"A randomized cross-over trial of prebiotics and probiotics in multiple sclerosis: Trial feasibility, supplement tolerability and symptom abatement","volume":"89","author":"Farber R","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"e70871","key":"2026020612023815400_fcaf510-B39","article-title":"Longitudinal digital phenotyping of multiple sclerosis severity using passively sensed behaviors and ecological momentary assessments: real-world evaluation","volume":"27","author":"Xia","year":"2025","journal-title":"J Med Internet Res"},{"issue":"1","key":"2026020612023815400_fcaf510-B40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12974-025-03474-8","article-title":"Aging-dependent change in Th17 and cytokine response in multiple sclerosis","volume":"22","author":"Zhu","year":"2025","journal-title":"J Neuroinflammation"},{"issue":"2","key":"2026020612023815400_fcaf510-B41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"2026020612023815400_fcaf510-B42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3390\/ijms19082408","article-title":"Tau in oligodendrocytes takes neurons in sickness and in health","volume":"19","author":"LoPresti","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026020612023815400_fcaf510-B43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2026020612023815400_fcaf510-B44","doi-asserted-by":"crossref","first-page":"e1583","DOI":"10.1002\/wsbm.1583","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey","year":"2023","journal-title":"WIREs Mech Dis"},{"issue":"5","key":"2026020612023815400_fcaf510-B45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"University of California, San Francisco MS-EPIC Team","year":"2019","journal-title":"Ann Neurol"},{"key":"2026020612023815400_fcaf510-B46","first-page":"767083","article-title":"Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis","volume":"2011","author":"Dujmovic","year":"2011","journal-title":"Mult Scler Int"},{"issue":"1","key":"2026020612023815400_fcaf510-B47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1474-4422(04)00964-0","article-title":"Biological markers in CSF and blood for axonal degeneration in multiple sclerosis","volume":"4","author":"Teunissen","year":"2005","journal-title":"Lancet Neurol"},{"key":"2026020612023815400_fcaf510-B48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2026020612023815400_fcaf510-B49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","article-title":"Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease","volume":"14","author":"Kac","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"2026020612023815400_fcaf510-B50","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1111\/jnc.70114","article-title":"Equivalence of plasma and Serum for clinical measurement of p-tau217: Comparative analyses of four blood-based assays","volume":"169","author":"Chen","year":"2025","journal-title":"J Neurochem"},{"issue":"1","key":"2026020612023815400_fcaf510-B51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00401-024-02742-w","article-title":"Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions","volume":"147","author":"de Boer","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2026020612023815400_fcaf510-B52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2478\/s11536-011-0003-7","article-title":"CSF and serum total-tau and phospho-tau(181P) in MS patients","volume":"6","author":"Jaworski","year":"2011","journal-title":"Open Med"},{"issue":"3","key":"2026020612023815400_fcaf510-B53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1191\/1352458506ms1288sr","article-title":"Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis","volume":"12","author":"Guimar\u00e3es","year":"2006","journal-title":"Mult Scler"},{"issue":"6","key":"2026020612023815400_fcaf510-B54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1034\/j.1600-0404.2002.01370.x","article-title":"Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis","volume":"106","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2002","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"2026020612023815400_fcaf510-B55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000008181","article-title":"Increased cerebrospinal fluid tau protein in multiple sclerosis","volume":"43","author":"Kapaki","year":"2000","journal-title":"Eur Neurol"},{"key":"2026020612023815400_fcaf510-B56","doi-asserted-by":"crossref","first-page":"109476","DOI":"10.1016\/j.mehy.2019.109476","article-title":"Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis","volume":"135","author":"Mirzaii-Dizgah","year":"2020","journal-title":"Med Hypotheses"},{"issue":"3","key":"2026020612023815400_fcaf510-B57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/medicina60030416","article-title":"Pilot study of the total and phosphorylated tau proteins in early-stage multiple sclerosis","volume":"60","author":"Masiulien\u0117","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"2026020612023815400_fcaf510-B58","doi-asserted-by":"crossref","first-page":"105801","DOI":"10.1016\/j.msard.2024.105801","article-title":"Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis","volume":"90","author":"Emer\u0161i\u010d","year":"2024","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"2026020612023815400_fcaf510-B59","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: Current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol"},{"issue":"11","key":"2026020612023815400_fcaf510-B60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: Pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2026020612023815400_fcaf510-B61","doi-asserted-by":"crossref","first-page":"e200052","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"2026020612023815400_fcaf510-B62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neulet.2004.03.039","article-title":"Tau protein in cerebrospinal fluid: A possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis","volume":"363","author":"Mart\u0131\u0301nez-Y\u00e9lamos","year":"2004","journal-title":"Neurosci Lett"},{"key":"2026020612023815400_fcaf510-B63","doi-asserted-by":"crossref","first-page":"103231","DOI":"10.1016\/j.msard.2021.103231","article-title":"Cerebrospinal tau levels as a predictor of early disability in multiple sclerosis","volume":"56","author":"Virgilio","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"2026020612023815400_fcaf510-B64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/archneurol.2010.107","article-title":"Assessment of outcome predictors in first-episode acute myelitis: A retrospective study of 53 cases","volume":"67","author":"Gajofatto","year":"2010","journal-title":"Arch Neurol"},{"issue":"17","key":"2026020612023815400_fcaf510-B65","doi-asserted-by":"crossref","first-page":"e2378","DOI":"10.1212\/WNL.0000000000010629","article-title":"Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE \u03b54 genotype","volume":"95","author":"Babapour Mofrad","year":"2020","journal-title":"Neurology"},{"key":"2026020612023815400_fcaf510-B66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2021.04.003","article-title":"Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer\u2019s continuum: greater tau-PET retention in females","volume":"105","author":"Edwards","year":"2021","journal-title":"Neurobiol Aging."},{"issue":"S5","key":"2026020612023815400_fcaf510-B67","doi-asserted-by":"crossref","first-page":"e055785","DOI":"10.1002\/alz.055785","article-title":"Sex differences in levels of plasma neurofilament light and total tau in adults with Down syndrome","volume":"17","author":"Dang","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2026020612023815400_fcaf510-B68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-025-01684-z","article-title":"Sex differences in the association of Alzheimer\u2019s disease biomarkers and cognition in a multicenter memory clinic study","volume":"17","author":"Boccalini","year":"2025","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2026020612023815400_fcaf510-B69","doi-asserted-by":"crossref","first-page":"e70634","DOI":"10.1002\/alz.70634","article-title":"Sex differences in vulnerability to tau pathology: impact on cognitive decline.","volume":"21","author":"Zeighami","year":"2025","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"2026020612023815400_fcaf510-B70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13293-020-00310-x","article-title":"Sex differences in Alzheimer\u2019s-related Tau biomarkers and a mediating effect of testosterone","volume":"11","author":"Sundermann","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"11","key":"2026020612023815400_fcaf510-B71","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med"},{"issue":"1","key":"2026020612023815400_fcaf510-B72","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41467-025-57144-7","article-title":"Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis","volume":"16","author":"Abu-Rumeileh","year":"2025","journal-title":"Nat Commun"},{"issue":"10","key":"2026020612023815400_fcaf510-B73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41582-024-01017-y","article-title":"Tau phosphorylation correlates with multiple sclerosis disease course","volume":"20","author":"Wood","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2026020612023815400_fcaf510-B74","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","article-title":"Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer\u2019s disease","volume":"31","author":"Islam","year":"2025","journal-title":"Nat Med"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf510\/66196636\/fcaf510.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/1\/fcaf510\/66196636\/fcaf510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/1\/fcaf510\/66196636\/fcaf510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:02:51Z","timestamp":1770397371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf510\/8408229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf510","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcaf510"}}